Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-F roll-over benralizumab safety study
2025-523307-29-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in asthma, eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES), sponsored by AstraZeneca. Primary endpoint: Safety. Planned start Sep 2026; status: authorised.
02
Drugs
benralizumab
03
Conditions
asthmaeosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2025-523307-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523307-29-00.